Tumors with ALK or ROS1 Alteration

Trial  #

Trial Sub-type

Title

CLDK378AUS23

Sponsor:
Novatis

Patient has a confirmed diagnosis of a select solid tumor (except with a primary diagnosis of ALK+ NSCLC) or hematologic malignancy and is in need of treatment because of progression or relapse

Modular phase II study to link targeted therapy to patients with pathway activated tumors: Module 7 – Ceritinib (LDK378) for patients whose tumors have aberrations in ALK or ROS1